Bard Associates Inc. Sells 44,700 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Bard Associates Inc. lowered its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 14.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 267,699 shares of the medical instruments supplier’s stock after selling 44,700 shares during the quarter. Bard Associates Inc.’s holdings in Harvard Bioscience were worth $565,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. AMH Equity Ltd raised its position in shares of Harvard Bioscience by 4.7% in the fourth quarter. AMH Equity Ltd now owns 2,500,000 shares of the medical instruments supplier’s stock valued at $5,275,000 after purchasing an additional 111,132 shares during the period. Williams & Novak LLC bought a new stake in shares of Harvard Bioscience in the fourth quarter valued at approximately $209,000. JPMorgan Chase & Co. raised its position in shares of Harvard Bioscience by 63.0% in the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 11,397 shares during the period. Barclays PLC raised its position in shares of Harvard Bioscience by 304.4% in the third quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 44,150 shares during the period. Finally, Geode Capital Management LLC grew its stake in Harvard Bioscience by 2.2% during the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after acquiring an additional 19,972 shares in the last quarter. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Price Performance

Shares of NASDAQ:HBIO opened at $0.82 on Tuesday. The company has a 50 day moving average of $1.66 and a 200 day moving average of $2.20. The stock has a market cap of $35.77 million, a P/E ratio of -2.48 and a beta of 1.25. Harvard Bioscience, Inc. has a 12 month low of $0.81 and a 12 month high of $4.70. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.